peoplePerson
Shari Pilon-Thomas
Shari Pilon-Thomas is the immunologist behind Moffitt's TIL manufacturing and the biology of who responds.
Leads translational immunology for Moffitt's TIL and cell therapy programmes, studying tumour acidity and resistance to immunotherapy.
Role
Senior Member, Immunology; Scientific Director, Cellular Therapy
Institution
Specialisms
TIL therapyTumour immunologyImmunotherapy resistance
Profiles
| Title | Journal | Year |
|---|---|---|
| Neutralization of tumor acidity improves antitumor responses to immunotherapy | Cancer Research | 2016 |
Pages like this
not linked directly; found by shared links- PersonPatrick Hwu
Shares Moffitt Cancer Center, TIL therapy, Melanoma.
- PersonPamela S. Ohashi
Shares TIL therapy, Melanoma.
- PersonAmod A. Sarnaik
Shares Moffitt Cancer Center, TIL therapy, Melanoma.
- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Melanoma.
- IdeaSwitch drugs at maximum response, not at relapse
Shares Moffitt Cancer Center, Melanoma.
- CollectionMelanoma Research Alliance (MRA)
Shares TIL therapy, Melanoma.
- IdeaEvolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials
Shares Moffitt Cancer Center, Melanoma.
- IdeaA multi-cancer platform trial of adaptive (dose-holiday) therapy
Shares Moffitt Cancer Center, Melanoma.